Neumora Therapeutics, INC. (NMRA) — 8-K Filings

8-K Filings (12)

• Neumora Therapeutics Files 8-K on Financials — Mar 30, 2026 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its Results of Operations and Financial Condition. The filing includes financial stateme
• 8-K Filing — Nov 21, 2025
• Neumora Therapeutics Files 8-K — Oct 27, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting other events and financial statements. The company, formerly known as RBNC Therapeutics,
• Neumora Therapeutics Files 8-K on Security Holder Vote — May 30, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting on a matter submitted to a vote of its security holders on May 28, 2025. The company, formerl
• Neumora Therapeutics Faces Delisting Concerns — May 16, 2025 Risk: high
  Neumora Therapeutics, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the ef
• Neumora Therapeutics Files 8-K on Executive Changes — Feb 13, 2025 Risk: low
  On February 13, 2025, Neumora Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fi
• Neumora Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on financial statements and exhibits. The company, formerly known as RBNC Therapeutics, I
• Neumora Therapeutics Files 8-K — Jan 2, 2025 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on January 2, 2025, reporting other events and financial statements. The company, formerly known as RBNC Therapeutics, I
• Neumora Therapeutics Reports on Shareholder Vote — Jun 14, 2024 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on June 14, 2024, reporting on a matter submitted to a vote of its security holders on June 13, 2024. The company, forme
• Neumora Therapeutics Closes $349.6M Public Offering — Apr 15, 2024 Risk: medium
  On April 15, 2024, Neumora Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully sold 21,8
• Neumora Therapeutics Files 8-K on Financials — Mar 7, 2024 Risk: low
  Neumora Therapeutics, Inc. filed an 8-K on March 7, 2024, reporting on its results of operations and financial condition. The filing also includes financial sta
• Neumora Therapeutics Confirms Nasdaq Listing for NMRA Stock — Jan 8, 2024
  Neumora Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its common stock, with a $0.0001 par value per share, is registered on Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX